Qube Research & Technologies (QRT)
AUTL icon

Qube Research & Technologies (QRT)’s Autolus Therapeutics AUTL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,188
Closed -$79.3K – 3544
2025
Q1 		$79.3K Sell
51,188
-107,497
-68% -$218K ﹤0.01% 3036
2024
Q4 		$373K Sell
158,685
-206,310
-57% -$697K ﹤0.01% 2617
2024
Q3 		$1.32M Sell
364,995
-437,086
-54% -$1.74M ﹤0.01% 1927
2024
Q2 		$2.79M Buy
802,081
+753,506
+1,551% +$3.25M ﹤0.01% 1490
2024
Q1 		$310K Buy
48,575
+46,622
+2,387% +$291K ﹤0.01% 2792
2023
Q4 		$12.6K Sell
1,953
-8,315
-81% -$31.7K ﹤0.01% 3566
2023
Q3 		$23.9K Sell
10,268
-11,639
-53% -$33.2K ﹤0.01% 3096
2023
Q2 		$52.1K Buy
+21,907
New +$52K ﹤0.01% 2068

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AUTL Position: Q2 2025 in Review

Qube Research & Technologies (QRT) sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 51,188 shares — an estimated $79.3K sold.

Qube Research & Technologies (QRT) first reported a position in AUTL in Q2 2023 and held it in 8 quarters. The position peaked at $2.79M in Q2 2024. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

  • Qube Research & Technologies (QRT) reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 51,188 Autolus Therapeutics shares in Q2 2025, an estimated $79.3K.
  • Qube Research & Technologies (QRT) first reported a position in Autolus Therapeutics in Q2 2023 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Autolus Therapeutics position peaked at $2.79M in Q2 2024.
  • 94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.